Quadracel Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The quadracel market research report is one of a series of new reports that provides quadracel market statistics, including quadracel industry global market size, regional shares, competitors with quadracel market share, detailed quadracel market segments, market trends and opportunities, and any further data you may need to thrive in the quadracel industry. This quadracel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the expansion of immunization programs, rising number of government and private sector collaborations, growing focus on preventive healthcare, increasing healthcare spending, and development of new vaccines targeting emerging pathogens. Major trends in the forecast period include the integration of combination vaccines into routine childhood immunization schedules, advancements in needle-free vaccination methods, a growing focus on booster shots for long-term immunity, increasing research on improving vaccine efficacy, and a greater focus on global vaccine equity.

The rising incidence of vaccine-preventable diseases is expected to drive the growth of the Quadracel market in the future. Vaccine-preventable diseases (VPDs) are infectious diseases that can be avoided through vaccines, preventing complications and fatalities. The growing incidence of these diseases is a significant public health issue, influenced by factors such as insufficient vaccination coverage, evolving pathogens, and societal challenges. Quadracel is a vital vaccine that offers protection against multiple vaccine-preventable diseases in a single dose, helping to alleviate the burden of these illnesses and improve public health outcomes. For example, in August 2024, the UK Health Security Agency reported 368 measles cases in England in 2023, a nearly sevenfold increase from the 53 cases recorded in 2022, with the majority of cases concentrated in the West Midlands and London. As such, the increasing occurrence of vaccine-preventable diseases is contributing to the market's growth.

The increasing prevalence of infectious diseases is another factor expected to support the growth of the Quadracel market. Infectious diseases are caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, that invade the body and cause symptoms and potentially serious health complications. The rising frequency of these diseases is attributed to several factors, such as antimicrobial resistance, globalization, urbanization, climate change, and insufficient vaccination coverage. Quadracel is effective in addressing these diseases by providing a combination vaccine that protects against diphtheria, tetanus, pertussis, and polio. For instance, the Centers for Disease Control and Prevention reported in December 2024 that pertussis cases in the United States increased more than sixfold by week 47 compared to the same period in 2023, signaling a return to typical trends. Consequently, the growing prevalence of infectious diseases is fostering the growth of the Quadracel market.

Government initiatives are also expected to boost the Quadracel market in the coming years. These initiatives are driven by several factors, including growing public health concerns, rising healthcare costs, global health challenges, and increasing public demand for better healthcare services. Governments play a crucial role in promoting the Quadracel vaccine by ensuring its availability, affordability, and widespread distribution to prevent various infectious diseases. For example, in May 2024, the United States Department of Health and Human Services published its Fiscal Year 2024 Budget, which includes $144.3 billion in discretionary budget authority and $1.7 trillion in mandatory funding. This increase from the FY 2022 proposal reflects the government’s continued investment in public health. Therefore, the expansion of government initiatives is positively impacting the growth of the Quadracel market.

The key company operating in the quadracel market is Sanofi Pasteur Limited.

North America was the largest region in the quadracel market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in quadracel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the quadracel market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Quadracel is a combination vaccine designed to protect children aged 4 to 6 years against diphtheria, tetanus, pertussis (whooping cough), and poliomyelitis. It contains inactivated poliovirus and acellular pertussis components, ensuring both safety and effectiveness. Approved for routine pediatric vaccination, this vaccine simplifies immunization schedules by combining multiple antigens into a single dose.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary forms of Quadracel are the DTaP-IPV vaccine and other combination vaccines. The DTaP-IPV vaccine is a combined immunization that protects against diphtheria, tetanus, pertussis, and polio, and is typically administered to children. Quadracel is indicated for diphtheria, tetanus, pertussis, and poliomyelitis prevention. It is used in pediatric vaccination, adult vaccination, travel vaccination programs, and for healthcare workers. The vaccine is distributed through various channels including hospitals, clinics, vaccination centers, government health programs, and private healthcare providers.

The quadracel market consists of sales of products such as combination vaccines and single-dose vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.